Standard BioTools Inc
LAB1.260USD
+0.020+1.61%
Cierre 02/06, 16:00（ET）Cotizaciones retrasadas 15 min
483.35MCap. mercado
PérdidaP/E TTM
Más Datos de Standard BioTools Inc Compañía
Standard BioTools Inc. develops, manufactures and sells a diversified range of instrumentation, consumables, and services that help scientists and biomedical researchers. The Company's segments include Proteomics and Genomics. The Proteomics segment includes instruments, consumables, software, and services based upon technologies used in the identification of proteins. The Genomics segment includes instruments, consumables, software, and services based upon technologies used in the identification of genes (DNA, RNA) and their functions. The Company works with academic, government, pharmaceutical, biotechnology, plant and animal research, and clinical laboratories worldwide, focusing on the most pressing needs in translational and clinical research, including oncology, immunology, and immunotherapy. It offers a diverse range of instrumentation, consumables, and services that generate data across early discovery, translational and clinical research.
Información de Standard BioTools Inc
Símbolo de cotizaciónLAB
Nombre de la empresaStandard BioTools Inc
Fecha de salida a bolsaFeb 10, 2011
Director ejecutivoEgholm (Michael)
Número de empleados818
Tipo de seguridadOrdinary Share
Fin del año fiscalFeb 10
Dirección2 Tower Place
CiudadSOUTH SAN FRANCISCO
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal94080
Teléfono16502666000
Sitio Webhttps://www.standardbio.com/
Símbolo de cotizaciónLAB
Fecha de salida a bolsaFeb 10, 2011
Director ejecutivoEgholm (Michael)
Ejecutivos de Standard BioTools Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Fenel M. Eloi
Mr. Fenel M. Eloi
Independent Director
Independent Director
157.01K
+94592.00%
Mr. Sean Mackay
Mr. Sean Mackay
Chief Business Officer
Chief Business Officer
65.77K
-19661.00%
Dr. Franklin R. (Frank) Witney, Ph.D.
Dr. Franklin R. (Frank) Witney, Ph.D.
Independent Director
Independent Director
--
--
Dr. Michael Egholm, Ph.D.
Dr. Michael Egholm, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Hanjoon Alex Kim
Mr. Hanjoon Alex Kim
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Eli D. Casdin
Mr. Eli D. Casdin
Independent Director
Independent Director
--
--
Mr. Thomas (Tom) Carey
Mr. Thomas (Tom) Carey
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Ms. Kathy Hibbs
Ms. Kathy Hibbs
Independent Director
Independent Director
--
--
Mr. Troy Cox
Mr. Troy Cox
Independent Director
Independent Director
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Fenel M. Eloi
Mr. Fenel M. Eloi
Independent Director
Independent Director
157.01K
+94592.00%
Mr. Sean Mackay
Mr. Sean Mackay
Chief Business Officer
Chief Business Officer
65.77K
-19661.00%
Dr. Franklin R. (Frank) Witney, Ph.D.
Dr. Franklin R. (Frank) Witney, Ph.D.
Independent Director
Independent Director
--
--
Dr. Michael Egholm, Ph.D.
Dr. Michael Egholm, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Hanjoon Alex Kim
Mr. Hanjoon Alex Kim
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Eli D. Casdin
Mr. Eli D. Casdin
Independent Director
Independent Director
--
--
Desglose de ingresos
Divisa: USDActualizado: mar., 6 de ene
Divisa: USDActualizado: mar., 6 de ene
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
Por negocioUSD
Nombre
Ganancia
Proporción
Consumables
8.71M
44.52%
Services and other revenue
5.75M
29.42%
Instruments
5.09M
26.06%
Por regiónUSD
Nombre
Ganancia
Proporción
Americas
7.84M
40.11%
Europe & Middle East & Africa (EMEA)
7.25M
37.06%
Asia-Pacific
4.46M
22.84%
Por negocio
Por región
Por negocioUSD
Nombre
Ganancia
Proporción
Consumables
8.71M
44.52%
Services and other revenue
5.75M
29.42%
Instruments
5.09M
26.06%
Estadísticas de accionistas
Actualizado: sáb., 15 de nov
Actualizado: sáb., 15 de nov
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Casdin Capital, LLC
23.09%
Viking Global Investors LP
15.25%
BlackRock Institutional Trust Company, N.A.
5.67%
MAK Capital One, LLC
5.19%
The Vanguard Group, Inc.
4.48%
Otro
46.31%
Accionistas
Accionistas
Proporción
Casdin Capital, LLC
23.09%
Viking Global Investors LP
15.25%
BlackRock Institutional Trust Company, N.A.
5.67%
MAK Capital One, LLC
5.19%
The Vanguard Group, Inc.
4.48%
Otro
46.31%
Tipos de accionistas
Accionistas
Proporción
Hedge Fund
33.44%
Investment Advisor/Hedge Fund
27.49%
Investment Advisor
14.80%
Individual Investor
2.53%
Research Firm
0.66%
Venture Capital
0.57%
Bank and Trust
0.24%
Pension Fund
0.11%
Insurance Company
0.02%
Otro
20.13%
Participación institucional
Actualizado: jue., 1 de ene
Actualizado: jue., 1 de ene
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q4
332
297.38M
77.33%
-29.00M
2025Q3
324
277.96M
72.29%
-27.47M
2025Q2
337
283.64M
74.68%
-28.24M
2025Q1
336
286.88M
75.60%
-24.96M
2024Q4
322
279.84M
75.18%
-22.14M
2024Q3
315
282.67M
78.53%
-14.93M
2024Q2
303
268.49M
74.97%
-14.97M
2024Q1
306
263.03M
71.99%
+131.65M
2023Q4
264
54.09M
66.99%
-14.10M
2023Q3
265
53.37M
67.31%
-13.39M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Casdin Capital, LLC
88.78M
23.09%
+350.00K
+0.40%
Dec 04, 2025
Viking Global Investors LP
58.65M
15.25%
--
--
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
21.81M
5.67%
+20.05K
+0.09%
Sep 30, 2025
MAK Capital One, LLC
15.93M
4.14%
+10.33M
+184.63%
Sep 30, 2025
The Vanguard Group, Inc.
17.19M
4.47%
+263.85K
+1.56%
Sep 30, 2025
Long Focus Capital Management LLC
11.36M
2.95%
+1.29M
+12.84%
Sep 30, 2025
Geode Capital Management, L.L.C.
7.47M
1.94%
+27.78K
+0.37%
Sep 30, 2025
State Street Investment Management (US)
6.40M
1.66%
+101.35K
+1.61%
Sep 30, 2025
Hollow Brook Wealth Management, LLC
5.78M
1.5%
+165.43K
+2.95%
Sep 30, 2025
Morgan Stanley Investment Management Inc. (US)
5.64M
1.47%
+285.46K
+5.33%
Sep 30, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 6 de dic
Actualizado: sáb., 6 de dic
Nombre
Proporción
Invesco NASDAQ Future Gen 200 ETF
0.51%
ARK Genomic Revolution ETF
0.33%
iShares Micro-Cap ETF
0.07%
iShares Biotechnology ETF
0.04%
iShares Russell 2000 Value ETF
0.03%
ProShares Hedge Replication ETF
0.02%
ProShares UltraPro Russell2000
0.02%
iShares Russell 2000 ETF
0.01%
Global X Russell 2000 ETF
0.01%
Fidelity MSCI Health Care Index ETF
0.01%
Ver más
Invesco NASDAQ Future Gen 200 ETF
Proporción0.51%
ARK Genomic Revolution ETF
Proporción0.33%
iShares Micro-Cap ETF
Proporción0.07%
iShares Biotechnology ETF
Proporción0.04%
iShares Russell 2000 Value ETF
Proporción0.03%
ProShares Hedge Replication ETF
Proporción0.02%
ProShares UltraPro Russell2000
Proporción0.02%
iShares Russell 2000 ETF
Proporción0.01%
Global X Russell 2000 ETF
Proporción0.01%
Fidelity MSCI Health Care Index ETF
Proporción0.01%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Fecha ex-dividendo
Tipo
Relación
Sin datos
Fecha
Fecha ex-dividendo
Tipo
Relación
Sin datos
